
    
      A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an
      OCT2 Substrate, in Healthy Subjects When administered Alone and in Combination with a Single
      Oral Dose of Vandetanib (CAPRELSA) 800 mg
    
  